Abstract
Therapeutic communities have a long history, dating back to the Middle Ages. Beginning in the mid 20th century, the therapeutic community was revived in the form of such programs as Synanon, led by former substance abusers. Subsequent TCs have built upon the early principles of Synanon but adapted to meet the changing needs of clients and incorporated what has been learned from the expansion of the knowledge base of substance abuse treatment. Most notably, psychiatrists have come to play an important role as medical directors of TCs. This paper describes the adolescent treatment program at Daytop Village in terms of its functioning and patient population, and the role of the psychiatrist-medical director. Necessary adaptations to the TC model for adolescents are explained. The literature on outcome of this type of treatment with respect to adolescents is reviewed. The evidence suggests that therapeutic communities are an effective form of treatment for adolescent substance abusers.
Keywords: Adolescent substance abuse related disorders/treatment, therapeutic community, adolescents, residential treatment, Synanon, substance abusers, TCs, substance abuse treatment, adaptations, Daytop Village
Adolescent Psychiatry
Title: The Therapeutic Community for the Adolescent Substance Abuser
Volume: 1 Issue: 2
Author(s): Gregory C. Bunt and Britta Muehlbach
Affiliation:
Keywords: Adolescent substance abuse related disorders/treatment, therapeutic community, adolescents, residential treatment, Synanon, substance abusers, TCs, substance abuse treatment, adaptations, Daytop Village
Abstract: Therapeutic communities have a long history, dating back to the Middle Ages. Beginning in the mid 20th century, the therapeutic community was revived in the form of such programs as Synanon, led by former substance abusers. Subsequent TCs have built upon the early principles of Synanon but adapted to meet the changing needs of clients and incorporated what has been learned from the expansion of the knowledge base of substance abuse treatment. Most notably, psychiatrists have come to play an important role as medical directors of TCs. This paper describes the adolescent treatment program at Daytop Village in terms of its functioning and patient population, and the role of the psychiatrist-medical director. Necessary adaptations to the TC model for adolescents are explained. The literature on outcome of this type of treatment with respect to adolescents is reviewed. The evidence suggests that therapeutic communities are an effective form of treatment for adolescent substance abusers.
Export Options
About this article
Cite this article as:
C. Bunt Gregory and Muehlbach Britta, The Therapeutic Community for the Adolescent Substance Abuser, Adolescent Psychiatry 2011; 1 (2) . https://dx.doi.org/10.2174/2210676611101020122
DOI https://dx.doi.org/10.2174/2210676611101020122 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding
Current Neuropharmacology Computational Approaches to Screen Candidate Ligands with Anti- Parkinson’s Activity Using R Programming
Current Topics in Medicinal Chemistry Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease
Current Alzheimer Research Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation
Current Topics in Medicinal Chemistry A Case of Topiramate-Induced Epistaxis
Current Drug Safety Investigation on the Development of Losartan Potassium Sustained Release Microspheres by Solvent Evaporation Methods
Micro and Nanosystems PET and SPECT Radiotracers to Assess Function and Expression of ABC Transporters In Vivo
Current Drug Metabolism Is Covalently Crosslinked Aβ Responsible for Synaptotoxicity in Alzheimers Disease?
Current Alzheimer Research [<sup>18</sup>F]-florbetaben PET/CT Imaging in the Alzheimer’s Disease Mouse Model APPswe/PS1dE9
Current Alzheimer Research Editorial (Hot Topic: Organic Solute Transporters and Diseases: Potential Therapeutic Targets)
Current Molecular Pharmacology Soy Isoflavone Alleviates Aβ1-42-Induced Impairment of Learning and Memory Ability Through the Regulation of RAGE/LRP-1 in Neuronal and Vascular Tissue
Current Neurovascular Research Pathophysiology of Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Dietary Patterns in Alzheimers Disease and Cognitive Aging
Current Alzheimer Research Editorial [Hot Topic: Astrocytic Signal Transduction in CNS Disease and Therapy (Guest Editor: Liang Peng)]
Current Signal Transduction Therapy 4-Hydroxynonenal in the Pathogenesis and Progression of Human Diseases
Current Medicinal Chemistry Targeting the JNK Signaling Pathway for Stroke and Parkinsons Diseases Therapy
Current Drug Targets - CNS & Neurological Disorders Neurotransmitters and Microglial-Mediated Neuroinflammation
Current Protein & Peptide Science Meet Our Editorial Board Member:
Current Neuropharmacology Nerve Agents’ Surrogates: Invaluable Tools for Development of Acetylcholinesterase Reactivators
Current Organic Chemistry Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology